These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1067 related articles for article (PubMed ID: 30332562)
1. Pathophysiology of Sickle Cell Disease. Sundd P; Gladwin MT; Novelli EM Annu Rev Pathol; 2019 Jan; 14():263-292. PubMed ID: 30332562 [TBL] [Abstract][Full Text] [Related]
2. The Red Blood Cell-Inflammation Vicious Circle in Sickle Cell Disease. Nader E; Romana M; Connes P Front Immunol; 2020; 11():454. PubMed ID: 32231672 [TBL] [Abstract][Full Text] [Related]
3. Heme triggers TLR4 signaling leading to endothelial cell activation and vaso-occlusion in murine sickle cell disease. Belcher JD; Chen C; Nguyen J; Milbauer L; Abdulla F; Alayash AI; Smith A; Nath KA; Hebbel RP; Vercellotti GM Blood; 2014 Jan; 123(3):377-90. PubMed ID: 24277079 [TBL] [Abstract][Full Text] [Related]
5. The role of blood rheology in sickle cell disease. Connes P; Alexy T; Detterich J; Romana M; Hardy-Dessources MD; Ballas SK Blood Rev; 2016 Mar; 30(2):111-8. PubMed ID: 26341565 [TBL] [Abstract][Full Text] [Related]
6. Newer aspects of the pathophysiology of sickle cell disease vaso-occlusion. Conran N; Franco-Penteado CF; Costa FF Hemoglobin; 2009; 33(1):1-16. PubMed ID: 19205968 [TBL] [Abstract][Full Text] [Related]
7. Targeting novel mechanisms of pain in sickle cell disease. Tran H; Gupta M; Gupta K Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):546-555. PubMed ID: 29222304 [TBL] [Abstract][Full Text] [Related]
8. Targeting novel mechanisms of pain in sickle cell disease. Tran H; Gupta M; Gupta K Blood; 2017 Nov; 130(22):2377-2385. PubMed ID: 29187376 [TBL] [Abstract][Full Text] [Related]
9. Sickle cell disease: current treatment and emerging therapies. Neumayr LD; Hoppe CC; Brown C Am J Manag Care; 2019 Nov; 25(18 Suppl):S335-S343. PubMed ID: 31809007 [TBL] [Abstract][Full Text] [Related]
10. Thromboinflammatory mechanisms in sickle cell disease - challenging the hemostatic balance. Conran N; De Paula EV Haematologica; 2020 Oct; 105(10):2380-2390. PubMed ID: 33054078 [TBL] [Abstract][Full Text] [Related]
11. MASP-2 and MASP-3 inhibitors block complement activation, inflammation, and microvascular stasis in a murine model of vaso-occlusion in sickle cell disease. Belcher JD; Nguyen J; Chen C; Abdulla F; Conglin R; Ivy ZK; Cummings J; Dudler T; Vercellotti GM Transl Res; 2022 Nov; 249():1-12. PubMed ID: 35878790 [TBL] [Abstract][Full Text] [Related]